Sidney Kimmel Cancer Center LAPS Institutional Collaboration

悉尼金梅尔癌症中心 LAPS 机构合作

• 批准号: 9886229
• 负责人: Steven Cohen
• 金额: $ 39.85万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9886229
• 关键词: Address; Advanced Malignant Neoplasm; American College of Radiology Imaging Network; Basic Science; Cancer Biology; Cancer Center; Catchment Area; Characteristics; Cities; Clinical Research; Clinical Trials; Clinical Trials Network; Clinical assessments; Collaborations; Communities; Complement; County; Delaware; Discipline; Eastern Cooperative Oncology Group; Education; Faculty; Fostering; Funding Opportunities; Goals; Health; Health system; Hospitals; Incidence; Industry; Infrastructure; Institution; Knowledge; Laboratories; Laboratory Research; Lead; Leadership; Malignant Neoplasms; NCI Center for Cancer Research; NCI-Designated Cancer Center; National Clinical Trials Network; New Jersey; Oncology; Oncology Group; Outreach Research; Participant; Patients; Pennsylvania; Philadelphia; Population Heterogeneity; Population Research; Positioning Attribute; Process; Protocols documentation; Radiation Therapy Oncology Group; Research; Research Personnel; Research Priority; Role; Shapes; Site; System; Technology; Time; Translational Research; Underserved Population; United States National Institutes of Health; base; bench to bedside; cancer care; career development; data quality; design; health equity; innovation; leadership development; member; mortality; outreach; performance site; population based; programs; rare cancer; research study; socioeconomics; symptom management

ABSTRACT The overarching goal of the Sidney Kimmel Cancer Center (SKCC) is to leverage research expertise to reduce the overall incidence, burden, and mortality from cancer in Greater Philadelphia and beyond. SKCC goals are realized through unique strengths in addressing cancer problems through collaboration across basic, clinical, and population research disciplines. SKCC is a NCI-designated cancer center nucleated at the Jefferson Health-Center City campus and enriched by fully integrated research components at Jefferson Health-Abington and Jefferson Health-Aria. Building on these strengths, SKCC focuses on addressing catchment area needs through nurturing transdisciplinary research, expanding innovative research capabilities, extending outreach and clinical research into the community, and enhancing the pace of bench-to-bedside discovery. The Jefferson Health system has expanded over the last 3 years and now includes a system of 12 Hospitals treating more than 8,000 new cancer cases annually. The SKCC catchment area includes Philadelphia, Montgomery, and Delaware counties in Pennsylvania, and Camden County in New Jersey. Philadelphia's highly diverse population, with numerous socioeconomic, racial, and health challenges characteristic of major northeastern cities, shapes SKCC research priorities and outreach. At any given time, hundreds of research studies are underway at the cancer center, ranging from basic laboratory research to clinical assessments of new treatments to meet the needs of this diverse population. Many of these studies are collaborative, involving other cancer centers or other partners in industry and the community. The overall objective and goal of this proposal is to enable SKCC to participate as a Lead Academic Participating Site (LAPS) in the NCI National Clinical Trial Network (NCTN) Clinical Research Program. This goal will be achieved through providing scientific leadership for development and execution of NCTN trials complemented by an integrated and collaborative research program. The SKCC has an established and well supported infrastructure to nurture discoveries and processes that advance our fundamental knowledge of cancer biology and implementing them into the community. As an NCI-designated Cancer Center, SKCC addresses the cancer needs of a diverse population through integration of laboratory and population-based clinical research, engagement of the community in relevant research to identified challenges, outreach, and education regarding clinical trials. We propose the following specific aims in this LAPS application: Specific Aim 1: Deliver and enhance access to the most advanced cancer care through participation and dissemination of NCTN initiatives including trials for rare tumors across the SKCC. Specific Aim 2: Promote and support the scientific leadership within the NCTN. Specific Aim 3: To foster junior faculty investigators' career development through NCTN participation in both NCTN/NCI committee engagement and as key contributors to conceptual protocol designs.

摘要 Sidney Kimmel癌症中心（SKCC）的首要目标是利用研究专业知识， 大费城及其他地区癌症的总体发病率、负担和死亡率。SKCC的目标是 通过基础，临床， 和人口研究学科。SKCC是一个NCI指定的癌症中心，位于杰斐逊 健康中心城市校园，并通过杰斐逊健康-阿宾顿完全集成的研究组件丰富 和杰斐逊健康公司的艾瑞亚在这些优势的基础上，SKCC专注于满足集水区的需求 通过培养跨学科研究，扩大创新研究能力， 和临床研究进入社区，并加快从实验室到临床的发现步伐。的 杰斐逊卫生系统在过去3年中扩大，现在包括12家医院的系统 每年治疗8,000多例新发癌症病例。SKCC集水区包括费城， 宾夕法尼亚州的蒙哥马利和特拉华州县，以及新泽西的卡姆登县。费城的 高度多样化的人口，具有许多社会经济、种族和健康挑战， 东北部城市，形状SKCC的研究重点和推广。在任何时候，数百项研究 癌症中心正在进行研究，从基础实验室研究到临床评估， 新的治疗方法来满足这一多样化人群的需求。其中许多研究是合作的，涉及 其他癌症中心或行业和社区的其他合作伙伴。本项目的总体目标和目的 该提案旨在使SKCC能够作为牵头学术参与研究中心（LAPS）参与NCI国家 临床试验网络（NCTN）临床研究计划。这一目标将通过提供 科学领导NCTN试验的开发和执行， 合作研究计划。SKCC拥有完善的基础设施， 这些发现和过程推进了我们对癌症生物学的基础知识， 融入社区作为一个NCI指定的癌症中心，SKCC解决了癌症的需求， 通过整合实验室和基于人群的临床研究， 社区参与相关研究，以确定有关临床试验的挑战，推广和教育。我们 在LAPS应用程序中提出以下具体目标：具体目标1：提供并加强获得 通过参与和传播NCTN倡议，包括试验， SKCC中的罕见肿瘤具体目标2：促进和支持科学界的领导作用 NCTN。具体目标3：通过NCTN的参与，促进初级教师调查员的职业发展 参与NCTN/NCI委员会的工作，并作为概念性协议设计的关键贡献者。